This announcement is a separate document:
神州细胞自愿披露关于控股子公司产品SCTC21C获得药物临床试验批准通知书的公告
Shenzhou Cell voluntarily disclosed the announcement that the holding subsidiary product SCTC21C obtained a notice of approval for drug clinical trials
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.